“Targeting DNA packaging” means targeting chromatin: the DNA, histone proteins and regulatory machinery that help control which genes a cell uses. In leukaemia, abnormal chromatin regulation can help cancer cells survive or remain immature, so treatments aimed at particular chromatin dependencies are being developed. They are not one treatment for all leukaemias: the relevant target, evidence and potential use depend on the cancer’s molecular features.
What does DNA packaging have to do with genes?
Most DNA in a cell is wrapped around histone proteins and organized with other molecules into chromatin. This packaging is not just structural. It helps determine which genes are accessible and active. Enzymes and protein complexes can add, remove or interpret chemical marks on chromatin, or remodel its structure, changing gene activity without changing the DNA sequence itself.
As an Amazon Associate I earn from qualifying purchases.
In leukaemia, genetic alterations and epigenetic changes can work together. Abnormal regulation may affect cell growth, maturation, DNA repair and cell death. That gives researchers a reason to test drugs against chromatin-related machinery; it does not show that changing a chromatin mark will cure a patient’s leukaemia. Bhalla’s 2005 review and a 2017 review of chromatin modulators in acute myeloid leukaemia (AML) describe this therapeutic rationale.
Recommended Free Tools
What does a chromatin-targeting drug target?
The phrase covers a family of approaches, not a drug that repackages all of a cell’s DNA. A medicine might block a protein interaction, inhibit an enzyme that adds or removes a mark, or interfere with a complex that reads or remodels chromatin. The intent is to disrupt a dependency that is especially important to a particular leukaemia, while clinical studies must establish whether that translates into benefit and what harms it may cause.
#1 Best Overall
Why molecular subtype matters
AML illustrates why these treatments are discussed in molecular rather than one-size-fits-all terms. In AML with a KMT2A rearrangement or an NPM1 mutation, review literature links abnormal menin–KMT2A and Polycomb networks with expression of genes associated with leukaemic-cell self-renewal. Menin–KMT2A inhibitors are designed to interrupt that dependency and may encourage leukaemic cells to differentiate. This is a biological rationale, not evidence that every person with either alteration will respond.
The relevant biomarker, the wider genetic context and the treatment setting all matter. A target discussed in one AML subtype should not be assumed relevant to other AML cases, or to other forms of leukaemia.
Rank #2
- Great extension activities for science and biology
- Correlated to standards
- Comprehensive biology vocabulary study
- Fascinating true-to-life illustrations
How the main research approaches differ
A 2025 review by Perner and colleagues surveys several chromatin-associated targets in leukaemia and solid tumours. The list below describes the approaches covered in review literature, not a ranking of treatments. The reviews do not provide comparable patient-outcome data that would support ranking them.
| Target or pathway | What is being targeted | Context and evidence qualification |
|---|---|---|
| Menin–KMT2A | The interaction between menin and KMT2A-associated machinery, rather than a general alteration to DNA packaging. | Discussed in AML with KMT2A rearrangements and NPM1 mutations. Reviews describe early clinical promise, but also resistance and unanswered questions about patient selection and treatment sequencing. |
| DOT1L | A chromatin-associated enzyme. | Included among targets under investigation in the 2025 review; the reviewed material does not establish a general approved leukaemia use. |
| KDM1A | An enzyme that modifies chromatin-associated marks. | Included among chromatin-directed approaches in the 2025 review; subtype-specific clinical benefit is not established here. |
| Polycomb complexes | Protein complexes involved in chromatin regulation and gene silencing. | Reviewed in the context of AML networks, including KMT2A-rearranged and NPM1-mutated disease; a mechanistic link is not itself a patient outcome. |
| PRMT5 | An enzyme involved in protein modification and gene regulation. | Listed as a target in the 2025 review; the reviewed material does not establish a general approved leukaemia use. |
| IDH1/2 | Mutant metabolic enzymes that can disrupt normal epigenetic regulation. | The 2025 review reports FDA-approved uses of IDH1/2 inhibitors in specified IDH-mutant glioma, cholangiocarcinoma and myeloid malignancy settings, while describing other compounds in clinical trials. Approval is indication-specific, not a blanket approval for leukaemia. |
| SWI/SNF components | Parts of a complex that helps remodel chromatin structure. | Included among targets reviewed for therapeutic potential; the available reviews do not establish a general approved leukaemia use. |
Approved use is not the same as an investigational approach
Some drugs that act on epigenetic pathways have approved uses for particular cancers and molecular indications. The 2025 review reports FDA-approved uses for IDH1/2 inhibitors in specified IDH-mutant glioma, cholangiocarcinoma and myeloid malignancy settings. That does not mean every IDH inhibitor is approved, or that every person with leukaemia is eligible. Regulatory labels can differ by drug, disease, biomarker and country; check the current regulator label for the exact medicine and indication.
Other chromatin-directed compounds remain in clinical development, and a review’s mention of a target or compound does not establish that a trial is currently recruiting or that a treatment is available to a particular patient. Trial status and eligibility need to be checked in a current trial record with a clinician.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Resistance and unanswered clinical questions
Menin-targeting reviews describe promising early clinical results alongside therapy-resistant mutations. Researchers are also working through how best to select patients and how to sequence or combine treatments. Early results are not proof of durable benefit for everyone, and approaches aimed at different chromatin targets cannot be compared fairly without comparable clinical outcome and safety evidence.
For patients and families, the practical question is not simply whether a drug “targets DNA packaging.” It is whether there is evidence for that specific drug in the person’s leukaemia subtype and molecular profile, in the relevant treatment setting, and whether it is approved or being studied in a suitable trial.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
